Homology Medicines, Inc.·4

Apr 4, 4:24 PM ET

Novartis Institutes for BioMedical Research, Inc. 4

4 · Homology Medicines, Inc. · Filed Apr 4, 2018

Insider Transaction Report

Form 4
Period: 2018-04-02
Transactions
  • Conversion

    Common Stock

    2018-04-02+1,979,2261,979,226 total
  • Conversion

    Series B Preferred Stock

    2018-04-021,979,2260 total
    Common Stock (1,979,226 underlying)
Footnotes (2)
  • [F1]The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Common Stock held directly by NIBRI.
  • [F2]Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION